Rosalind Advisors Inc. Acquires Shares of 260,000 Replimune Group, Inc. (NASDAQ:REPL)

Rosalind Advisors Inc. acquired a new position in Replimune Group, Inc. (NASDAQ:REPL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 260,000 shares of the company’s stock, valued at approximately $3,149,000. Replimune Group accounts for approximately 1.6% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 18th biggest position.

A number of other institutional investors and hedge funds have also modified their holdings of the business. China Universal Asset Management Co. Ltd. boosted its position in shares of Replimune Group by 24.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock worth $198,000 after purchasing an additional 3,177 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Replimune Group by 14.7% during the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock worth $318,000 after buying an additional 3,374 shares during the period. MetLife Investment Management LLC grew its stake in shares of Replimune Group by 21.5% during the 3rd quarter. MetLife Investment Management LLC now owns 35,134 shares of the company’s stock worth $385,000 after acquiring an additional 6,216 shares in the last quarter. BNP Paribas Financial Markets grew its position in Replimune Group by 81.7% in the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after purchasing an additional 6,748 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Replimune Group by 8.3% in the 4th quarter. Rhumbline Advisers now owns 95,465 shares of the company’s stock valued at $1,156,000 after acquiring an additional 7,317 shares in the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Price Performance

Shares of REPL stock opened at $10.82 on Friday. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a market cap of $833.30 million, a P/E ratio of -3.52 and a beta of 1.30. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The business has a fifty day simple moving average of $12.66 and a 200 day simple moving average of $12.14.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Jefferies Financial Group increased their price objective on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets upped their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. HC Wainwright upped their price objective on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.